Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis by Yue-Wei Qian, Robert J. Schmidt, Youyan Zhang, Shaoyou Chu, Aimin Lin, He Wang, Xiliang Wang, Thomas P. Beyer, William R. Bensch, Weiming Li, Mariam E. Ehsani, Deshun Lu, Robert J. Konrad, Patrick I. Eacho, David E. Moller, Sotirios K. Karathanasis, Guoqing Cao

Subjects: “…proprotein convertase subtilisin/kexin type 9…”
Get full text

Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction by A. D. Gimadeeva, A. S. Galyavich, Z. M. Galeeva, L. V. Baleeva

Subjects: “…proprotein convertase subtilisin/kexin type 9…”
Get full text

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S] by Brandon Ason, José W.A. van der Hoorn, Joyce Chan, Edward Lee, Elsbet J. Pieterman, Kathy Khanh Nguyen, Mei Di, Susan Shetterly, Jie Tang, Wen-Chen Yeh, Margrit Schwarz, J. Wouter Jukema, Rob Scott, Scott M. Wasserman, Hans M.G. Princen, Simon Jackson

Subjects: Get full text

Functional analysis of sites within PCSK9 responsible for hypercholesterolemias⃞ by Shilpa Pandit, Doug Wisniewski, Joseph C. Santoro, Sookhee Ha, Vijayalakshmi Ramakrishnan, Rose M. Cubbon, Richard T. Cummings, Samuel D. Wright, Carl P. Sparrow, Ayesha Sitlani, Timothy S. Fisher

Subjects: “…proprotein convertase subtilisin/kexin type 9…”
Get full text

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol by Greg Welder, Issam Zineh, Michael A. Pacanowski, Jason S. Troutt, Guoqing Cao, Robert J. Konrad

Subjects: Get full text

Proprotein convertase subtilisin/kexin type 9 inhibitors: prospects for cholesterol-lowering therapy in type 2 diabetes by V.A. Serhiyenko, A.A. Serhiyenko

Subjects: Get full text

PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction by Hua Sun, Ronald M. Krauss, Jeffrey T. Chang, Ba-Bie Teng

Subjects: “…proprotein convertase subtilisin/kexin type 9…”
Get full text

Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients by Bruce A. Warden, PharmD, Tina Kaufman, PhD, PA-C, Jessica Minnier, PhD, P. Barton Duell, MD, Sergio Fazio, MD, PhD, Michael D. Shapiro, DO, MCR

Subjects: Get full text

Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Ci... by Ting‐Hsing Chao, I‐Chih Chen, Yi‐Heng Li, Po‐Tseng Lee, Shih‐Ya Tseng

Subjects: Get full text

Physical activity to reduce PCSK9 levels by Amedeo Tirandi, Fabrizio Montecucco, Fabrizio Montecucco, Luca Liberale, Luca Liberale

Subjects: “…proprotein convertase subtilisin/kexin type 9…”
Get full text

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis by Qianyun Guo, Xunxun Feng, Yujie Zhou

Subjects: Get full text

Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk by Renata Rajtar-Salwa, Beata Bobrowska, Sylwia Socha, Artur Dziewierz, Zbigniew Siudak, Jakub Batko, Stanisław Bartuś, Agata Krawczyk-Ożóg

Subjects: Get full text

Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice by Yi Luo, Laurie Warren, Donghui Xia, Heather Jensen, Thomas Sand, Stephen Petras, Wenning Qin, Kenneth S. Miller, Julie Hawkins

Subjects: Get full text

ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING by K. S. Benimetskaya, M. P. Yachmeneva, S. V. Astrakov, L. V. Shcherbakova, D. V. Denisova, Yu. I. Ragino, M. I. Voevoda

Subjects: “…proprotein convertase subtilisin/kexin type 9…”
Get full text

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy by Zhenxian Li, Haimei Zhu, Hao Liu, Dayue Liu, Jianhe Liu, Jiazheng Jiang, Yi Zhang, Zhang Qin, Yijia Xu, Yuan Peng, Bin Liu, Yun Long

Subjects: Get full text

The predictive utility of circulating PCSK9 levels on diabetes mellitus by Jia Peng, Cheng-Gang Zhu, Jian-Jun Li

Subjects: “…Proprotein convertase subtilisin/kexin type 9…”
Get full text

ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING by K. S. Benimetskaya, M. P. Yachmeneva, S. V. Astrakov, L. V. Shcherbakova, D. V. Denisova, Yu. I. Ragino, M. I. Voevoda

Subjects: “…proprotein convertase subtilisin/kexin type 9…”
Get full text

Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells[S] by Aiqin Cao, Minhao Wu, Hai Li, Jingwen Liu

Subjects: Get full text

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study by Dennis T. Ko, Anam M. Khan, Gynter Kotrri, Peter C. Austin, Harindra C. Wijeysundera, Maria Koh, Anna Chu, Cynthia A. Jackevicius, Patrick R. Lawler, Jack V. Tu

Subjects: Get full text

Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population by Wen Guo, Yingyun Gong, Yong Gu, Zhenzhen Fu, Hongqi Fan, Beibei Gao, Xiaohui Zhu, Jinxiang Fu, Yang Zhao, Min Sun, Xing Liu, Xian-Cheng Jiang, Tao Yang, Hongwen Zhou

Subjects: “…Proprotein convertase subtilisin/kexin type 9…”
Get full text